ELEVAI LABS, Inc. to Participate in Upcoming Aesthetic Industry Conferences
03 January 2024 - 1:15AM
ELEVAI LABS, INC., (NASDAQ: ELAB) a medical aesthetic company
specializing in physician-dispensed skincare, announces
participation in three aesthetic industry conferences in the first
quarter of 2024.
1. Octane Aesthetic
Technology Forum (ATF) in Newport Beach, California (January 24-25,
2024): ELEVAI's Third Consecutive Year as a Corporate Sponsor
ELEVAI is the ATF’s
2022 People’s Choice Award winner and a finalist for the 2023 Best
Consumer Innovation Award. The Octane ATF event is an invaluable
platform for industry leaders, experts, and innovators to converge
and discuss the latest trends, breakthroughs, and advancements in
aesthetic technology.
2. International
Master Course on Aging Science (IMCAS) World Congress in Paris (Feb
1-3, 2024): Jordan R. Plews, PhD to Participate on Distinguished
Panel Focused on Exosomes and Regenerative Aesthetics
Jordan R. Plews PhD,
ELEVAI’s Chief Executive Officer, a globally recognized expert in
the field of regenerative aesthetics, has been invited to
participate in a highly anticipated panel discussion at the IMCAS
in Paris. Dr. Plews will discuss the latest advancements in
exosomes and their applications in medical aesthetics and
physician-dispensed skincare. This conference marks the 25th
anniversary of the largest scientific aesthetics congress worldwide
gathering 15,000 plastic surgeons, dermatologists, and medical
aesthetic practitioners.
3. Aesthetic &
Anti-Aging Medicine World Congress (AMWC) Americas in Miami
(February 21-24, 2024): ELEVAI to Exhibit and Sponsor Product
Workshop on PREx TechnologyTM and Award-Winning ELEVAI E-SeriesTM
Peri-Procedure Topical Exosome Product Range
In addition to
exhibiting its innovative products at AMWC, ELEVAI will also lead a
product workshop discussing stem cell exosomes, its proprietary
PREx TechnologyTM, and the ELEVAI E-SeriesTM peri-procedure topical
exosome product range. The workshop aims to provide attendees with
a deeper understanding of ELEVAI's differentiated exosome
technology, fostering knowledge exchange and collaboration within
the aesthetic medicine community. AMWC has over 100 expert faculty
members from over 60 countries and attracts thousands of attendees
each year.
“We look forward to
showcasing ELEVAI and our product line at these upcoming meetings
where the foremost experts in medical aesthetics worldwide convene
each year. It’s an honor to continue receiving invitations to
contribute our perspective and expertise on stem cells and exosomes
and share the science behind our products. It’s a significant
responsibility and privilege to lead these discussions amongst the
medical practitioners who are propelling this industry forward,”
says Dr. Jordan R. Plews.
About ELEVAI
Labs
ELEVAI Labs Inc.
(NASDAQ: ELAB) is a medical aesthetics company developing
cutting-edge physician-dispensed skin care applications. The
company solves unmet needs in the medical aesthetics space through
a combination of cutting-edge science-driven and next-generation
consumer applications. ELEVAI Labs develops topical aesthetic skin
care cosmetic products for the physician-dispensed market, with a
focus on leveraging a proprietary stem cell exosome technology. For
more information visit www.elevaiskincare.com.
Forward-Looking Statements
Certain statements
made in this press release are "forward-looking statements'' within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements may be identified using words such as "anticipate",
"believe", "expect", "estimate", "plan", "outlook", and "project"
and other similar expressions that predict or indicate future
events or trends or that are not statements of historical matters.
These forward-looking statements reflect the current analysis of
existing information and are subject to various risks and
uncertainties. As a result, caution must be exercised in relying on
forward-looking statements. Due to known and unknown risks, actual
results may differ materially from the Company’s expectations or
projections. The following factors, among others, could cause
actual results to differ materially from those described in these
forward-looking statements: (i) the failure to meet projected
research & development and production targets; (ii) changes in
applicable laws or regulations; and (iii) other risks and
uncertainties described herein, as well as those risks and
uncertainties discussed from time to time in other reports and
other public filings with the Securities and Exchange Commission
(the "SEC"). These statements are subject to uncertainties and
risks including, but not limited to, the uncertainties related to
market conditions and the completion of the initial public offering
on the anticipated terms or at all, and other factors discussed in
the “Risk Factors” section of the registration statement filed with
the SEC. The Company’s SEC filings are available publicly on the
SEC’s website at www.sec.gov. Any forward-looking statement made by
us in this press release is based only on information currently
available to the Company and speaks only as of the date on which it
is made. The Company undertakes no obligation to publicly update
any forward-looking statement, whether written or oral, that may be
made from time to time, whether because of new information, future
developments, or otherwise, except as required by law.
Media ContactBrenda BuechlerChief Marketing
Officercontact@elevailabs.com
Investor RelationsIR@elevailabs.com
Elevai Labs (NASDAQ:ELAB)
Historical Stock Chart
From Apr 2024 to May 2024
Elevai Labs (NASDAQ:ELAB)
Historical Stock Chart
From May 2023 to May 2024